natureresearch

Corresponding author(s):	Carlo Rivolta
Last updated by author(s):	Nov 20, 2020

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and theEditorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legand, table legand, main text, or Methods section

_				
·	トつ	+1	ıct	ics
	п		1 > 1	11 >

ГОІ	ali Si	adistical analyses, commit that the following items are present in the right elegand, table legand, main text, or interious section.
n/a	Co	nfirmed
	x	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
x		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X		A description of all covariates tested
	x	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	x	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
×		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
×		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated

Our web collection on $\underline{statistics\ for\ biologists}$ contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

No software was used for data collection.

Data analysis

Illumina Infinium arrays (San Diego, USA; GSAMD-24v2.0, GSA-24v2.0, CoreExome-24v1.1 and CoreExome-24v1.2) were analyzed with GenomeStudio (Illumina).

For exome sequencing, raw reads were mapped to the human genome reference sequence (build hg19) with the Novoalign software (V3.08.00, Novocraft Technologies, Selangor, Malaysia). Duplicate reads were then removed using Picard (v. 2.14.0-SNAPSHOT). Base quality score recalibration was performed and variant calling was done with HaplotypeCaller (GATK, v.4.0.3.0).

AutoMap is composed of Bash, Perl and R scripts. It was used with BCFTools (v1.9-78-gb7e4ba9), BEDTools (v2.25.0), Perl (v5.22.0), Bash (4.3.48(1)-release) and R (v3.5.1).

Probabilities for binomial distributions were calculated with the Perl script written by T.J. Finney (https://www.halotype.com/RKM/figures/TJF/binomial.txt).

Overlap of ROHs were obtained with BEDTools (v2.25.0) and the following command: bedtools intersect -a a.bed -b b.bed PLINK (v1.90b5) was used with default parameters for array data:

plink --bfile bfile --homozyg --out out --homozyg-window-het 1 --homozyg-density 50 --homozyg-gap 1000 --homozyg-window-missing 5 --homozyg-window-snp 50 --homozyg-snp 100 --homozyg-window-threshold 0.05 --homozyg-kb 1000

Samtools (v1.8): samtools mpileup -t DP,AD -ugf ref.fasta input.bam | bcftools call -vmO v -o out.vcf

 $Strelka\ (v2.9.2): configure Strelka Germline Workflow.py --bam\ input.bam\ --reference Fasta\ ref. fasta\ --exome$

HaplotypeCaller: gatk --java-options "-Xmx4g" HaplotypeCaller -R ref.fasta --dbsnp dbsnp.vcf -I \$input.bam -O out.vcf

AutoMap code is freely available on GitHub (https://github.com/mquinodo/AutoMap/).

The tools HomozygosityMapper for WES (no version), HOMWES (genomecombv0.98.8), BCFtools/RoH (v1.9-78-gb7e4ba9), FILTUS (v1.0.5), H3M2 (no version), SavvyHomozygosity (no version), and SavvyVcfHomozygosity (no version) were used with default parameters on exome data.

PLINK (v1.90b5) was used on exome data with the following command: plink --bfile bfile --homozyg --out out --homozyg-kb 1000 --homozyg-window-het 3 --homozyg-density 10000 --homozyg-gap 10000 --homozyg-window-missing 10 --homozyg-window-snp 20 --

T	nomozyg-snp 10homozyg-window-threshold 0.05mac 2
	70 1
F	For figures, RStudio (v1.0.153) was used with R (v3.5.1), gridExtra (v2.3) and ggplot2 (v3.3.2).

Ecological, evolutionary & environmental sciences

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

x Life sciences

Blinding

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets

Behavioural & social sciences

- A list of figures that have associated raw data
- A description of any restrictions on data availability

			4.4	
FIP	Id-c	necitic	reporting	5
1 10	iu J	PCCITIC		5

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life scier	nces study design		
All studies must dis	close on these points even when the disclosure is negative.		
Sample size	The training cohort is composed of 26 unrelated individuals. The validation cohort is composed of 26 unrelated individuals. These were all samples available to us and, as written in the text, provided sufficient power to our analysis.		
Data exclusions	No data was excluded.		
Replication	The validation was performed in 26 independent samples from the training cohort.		
Randomization	The 52 samples were splitted into the training and validation cohorts randomly by ethnicity (Portugal or Iran).		

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Reporting for specific materials, systems and methods

There was no blinding in the study, since this procedure is not applicable to our analysis.

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Ma	Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study	
×	Antibodies	×	ChIP-seq	
×	Eukaryotic cell lines	×	Flow cytometry	
×	Palaeontology	×	MRI-based neuroimaging	
×	Animals and other organisms			
	🗴 Human research participants			
x	Clinical data			

Human research participants

Policy information about studies involving human research participants

Population characteristics

The participants are coming from families with consanguineous parents either from Portugal or from Iran. The all suffer from inherited vision disorders. Please refer to Supplementary Data file 1 in which we included further details including gender and age

Recruitment

The participant were recruited in the framework of a project on genetics of diseases of the eye. Selection bias is not applicable to this study as we used all samples available to us.

Ethics oversight

Written informed consent forms were signed by all subjects, recruited at the Ophthalmic Hospital "Dr Gama Pinto" in Lisbon, and at the Fasa and Mashhad Universities of Medical Science in Iran. Ethical approval was obtained from Ethikkommission Nordwest-and Zentralschweiz, Ophthalmic Hospital "Dr Gama Pinto" in Lisbon, and Fasa and Mashhad Universities in Iran.

Note that full information on the approval of the study protocol must also be provided in the manuscript.